Patents by Inventor Johannes Gleitz

Johannes Gleitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aroylsemicarbazide derivatives against thromboembolic diseases
    Patent number: 7763611
    Abstract: Novel compounds of the formula (I) in which Het, R1, R2 and R3 have the meaning indicated in Patent claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors.
    Type: Grant
    Filed: May 12, 2004
    Date of Patent: July 27, 2010
    Assignee: Merck Patent GmbH
    Inventors: Werner Mederski, Christos Tsaklakidis, Dieter Dorsch, Bertram Cezanne, Johannes Gleitz
  • Prolinylarylacetamides
    Patent number: 7732481
    Abstract: Novel compounds of the formula (I), in which R, R1, R2, R3, X, X? and Y have the meaning indicated in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors.
    Type: Grant
    Filed: November 26, 2004
    Date of Patent: June 8, 2010
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Werner Mederski, Christos Tsaklakidis, Dieter Dorsch, Bertram Cezanne, Johannes Gleitz
  • Prolinyl derivatives for the treatment of thrombosis
    Patent number: 7683093
    Abstract: Novel compounds of the formula (I), in which R, R1, R2, R3 and R4 have the meaning indicated in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours.
    Type: Grant
    Filed: March 4, 2005
    Date of Patent: March 23, 2010
    Assignee: Merck Patent GmbH
    Inventors: Werner Mederski, Christos Tsaklakidis, Dieter Dorsch, Bertram Cezanne, Johannes Gleitz
  • Carboxamide derivatives and their use as factor Xa inhibitors
    Patent number: 7598241
    Abstract: Novel compounds of the formula (I) in which R1, D, X, W, Y and T have the meaning indicated in Patent Claim (1), e.g. (II), are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors.
    Type: Grant
    Filed: January 8, 2004
    Date of Patent: October 6, 2009
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Bertram Cezanne, Werner Mederski, Christos Tsaklakidis, Johannes Gleitz, Christoph van Amsterdam
  • 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS
    Publication number: 20090227631
    Abstract: The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Application
    Filed: November 22, 2006
    Publication date: September 10, 2009
    Inventors: Denis Carniato, Christine Charon, Johannes Gleitz, Didier Roche, Bjoern Hock
  • Carboxamides
    Patent number: 7579346
    Abstract: Novel compounds of the formula (I), in which D, W, X, Y, T, m and R1 have the meaning indicated in Patent claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours.
    Type: Grant
    Filed: October 30, 2003
    Date of Patent: August 25, 2009
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Bertram Cezanne, Werner Mederski, Christos Tsaklakidis, Hanns Wurziger, Johannes Gleitz, Christoph van Amsterdam
  • Benzimidazole derivatives
    Patent number: 7566789
    Abstract: Novel compounds of the formula I in which D, X, X?, W, Y, T and R1 are as defined in Patent claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours.
    Type: Grant
    Filed: July 4, 2003
    Date of Patent: July 28, 2009
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Bertram Cezanne, Wrner Mederski, Christos Tsaklakidis, Johannes Gleitz, Christopher Barnes
  • 1-[(4-Ethynylphenyl)]-2-[(phenyl)]-pyrrolidine-1,2-dicarboxamide derivatives as inhibitors of coagulation factors Xa and VIIa for the treatment of thrombosis
    Patent number: 7557222
    Abstract: Novel compounds of the formula (I), in which R, R1, R2 and R3 are as defined in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors.
    Type: Grant
    Filed: May 27, 2004
    Date of Patent: July 7, 2009
    Assignee: Merck Patent GmbH
    Inventors: Werner Mederski, Christos Tsaklakidis, Dieter Dorsch, Bertram Cezanne, Johannes Gleitz
  • Pyrazolidine-1,2-dicarboxyldiphenylamide derivatives as coagulation factor Xa inhibitors for the treatment of thromboses
    Patent number: 7557102
    Abstract: Novel compounds of the formula (I), in which R, R1, R2 and R3 have the meanings indicated in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors.
    Type: Grant
    Filed: March 9, 2004
    Date of Patent: July 7, 2009
    Assignee: Merck Patent GmbH
    Inventors: Werner Mederski, Christos Tsaklakidis, Dieter Dorsch, Bertram Cezanne, Johannes Gleitz
  • GLYCOPROTEIN VI FUSION PROTEINS
    Publication number: 20090155897
    Abstract: The present invention relates to Glycoprotein VI (GPVI) fusion proteins (GPVI-fusion proteins) comprising a tag like myc, GST, HA, FLAG, STREP but preferably a Immunoglobulin molecule (Ig), more preferably a Fc portion of said Ig and a protein or oligopeptide having the biological activity of GPVI (GPVI-like protein) which is binding to collagen and their use in methods and kits for the screening of potential agonists or antagonists for GPVI-collagen and/or platelet-collagen interaction is disclosed. Further, pharmaceutical compositions and therapeutic methods are provided comprising such GPVI-fusion proteins for the treatment of thrombotic and cardiovascular events and disorders related to GPVI-collagen and/or platelet-collagen interactions.
    Type: Application
    Filed: October 2, 2008
    Publication date: June 18, 2009
    Inventors: Christa BURGER, Johannes Gleitz, Mathias Frech
  • Glycoprotein VI fusion proteins
    Patent number: 7507412
    Abstract: The present invention relates to Glycoprotein VI (GPVI) fusion proteins (GPVI-fusion proteins) comprising a tag like myc, GST, HA, FLAG, STREP but preferably a Immunoglobulin molecule (Ig), more preferably a Fc portion of said Ig and a protein or oligopeptide having the biological activity of GPVI (GPVI-like protein) which is binding to collagen and their use in methods and kits for the screening of potential agonists or antagonists for GPVI-colagen and/or platelet-collagen interaction is disclosed. Further, pharmaaceutical compositions and therapeutic methods are provided comprising such GPVI-fusion proteins for the treatment of thrombotic and cardiovascular events and disorders related to GPVI-collagen and/or platelet-collagen interactions.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: March 24, 2009
    Assignee: Merck Patent GmbH
    Inventors: Christa Burger, Johannes Gleitz, Mathias Frech
  • Method for the production of pyrrolidine-1,2-dicarboxylic acid-1-(phenyl(-amide))-2(phenyl(-amide)) derivatives and 1-(phenylcarbamoyl)-pyrrolidine-2-carboxylic acid derivatives as intermediate products
    Patent number: 7504500
    Abstract: Process for the preparation of compounds of the formula I in which R, R1, R2 and R3 are as defined in Patent claim 1, and compounds of the formula IV in which R and R1 are as defined in Patent claim 1, are intermediates for the preparation of the compounds of the formula I.
    Type: Grant
    Filed: March 9, 2004
    Date of Patent: March 17, 2009
    Assignee: Merck Patent GmbH
    Inventors: Werner Mederski, Christos Tsaklakidis, Dieter Dorsch, Bertram Cezanne, Johannes Gleitz
  • Specific mechanism for inhibiting platelet adhesion to collagen
    Patent number: 7459438
    Abstract: The present invention relates to the polypeptide Saratin and its use for the manufacture of a medicament having the capability to significantly decrease platelet adhesion and platelet accumulation after vascular injuries or endarterectomy. The invention furthermore relates to a novel medical use of Saratin as an inhibitor of thrombosis and intimal hyperplasia, where the Saratin polypeptide may be used locally as a topical agent or as a coating on, or otherwise incorporated or associated with medical devices or vascular grafts.
    Type: Grant
    Filed: December 21, 2004
    Date of Patent: December 2, 2008
    Assignee: Merck Patent GmbH
    Inventors: Christopher Barnes, Matthias Frech, Uwe Hofmann, Johannes Gleitz, Wolfgang Strittmatter
  • Ethynyl derivatives as factor Xa inhibitors
    Patent number: 7427618
    Abstract: Novel compounds of the formula (I), in which R1, R2, R3, X and Y have the meaning indicated in Patent claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors.
    Type: Grant
    Filed: January 30, 2004
    Date of Patent: September 23, 2008
    Assignee: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Werner Mederski, Christos Tsaklakidis, Dieter Dorsch, Bertram Cezanne, Johannes Gleitz, Christoph van Amsterdam
  • Glycoprotein VI fusion proteins
    Publication number: 20080206247
    Abstract: The present invention relates to Glycoprotein VI (GPVI) fusion proteins (GPVI-fusion proteins) comprising a tag like myc, GST, HA, FLAG, STREP but preferably a Immunoglobulin molecule (Ig), more preferably a Fc portion of said Ig and a protein or oligopeptide having the biological activity of GPVI (GPVI-like protein) which is binding to collagen and their use in methods and kits for the screening of potential agonists or antagonists for GPVI-collagen and/or platelet-collagen interaction is disclosed. Further, pharmaceutical compositions and therapeutic methods are provided comprising such GPVI-fusion proteins for the treatment of thrombotic and cardiovascular events and disorders related to GPVI-collagen and/or platelet-collagen interactions.
    Type: Application
    Filed: November 27, 2007
    Publication date: August 28, 2008
    Inventors: Christa Burger, Johannes Gleitz, Mathias Frech
  • Carbonyl Compounds Which Can be Used as Inhibitors of Coagulation Factor Xa
    Publication number: 20080081814
    Abstract: Novel compounds of the formula (I), in which D, E, G, W, X, Y, T, R1 and R2 have the meaning indicated in Patent Claim (1), are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours.
    Type: Application
    Filed: September 1, 2005
    Publication date: April 3, 2008
    Inventors: Bertram Cezanne, Dieter Dorsch, Werner Mederski, Christos Tsaklakidis, Johannes Gleitz
  • Medicaments Comprising Carbonyl Compounds, And The Use Thereof
    Publication number: 20080003214
    Abstract: Use of compounds of the formula (I) in which D, E, G, W, X, Y, T, R1 and R2 have the meaning indicated in Patent Claim 1, for the prophylaxis and/or therapy of thromboembolic diseases
    Type: Application
    Filed: August 24, 2005
    Publication date: January 3, 2008
    Inventors: Bertram Cezanne, Dieter Dorsch, Werner Mederski, Christos Tsaklakidis, Johannes Gleitz
  • Proline Derivatives
    Publication number: 20070265259
    Abstract: Novel compounds of the formula (I), in which X, Y, R1, R2, R3, R4 and n have the meaning indicated in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours.
    Type: Application
    Filed: September 16, 2005
    Publication date: November 15, 2007
    Inventors: Werner Mederski, Christos Tsaklakidis, Dieter Dorsch, Bertram Cezanne, Johannes Gleitz
  • Phenyl derivatives
    Patent number: 7273867
    Abstract: Novel compounds of the formula I in which W, X, Y, T, R1 and R2 are as defined in Patent claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic disorders
    Type: Grant
    Filed: December 5, 2001
    Date of Patent: September 25, 2007
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Werner Mederski, Christos Tsaklakidis, Bertram Cezanne, Johannes Gleitz, Christopher Barnes
  • Dihydrobenzothiophenes
    Publication number: 20070219246
    Abstract: Compounds of the formula (I) in which W, R1, R2, R3, R4, and q have the meanings indicated in Claim 1, can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: April 28, 2005
    Publication date: September 20, 2007
    Inventors: Dirk Finsinger, Soheila Anzali, Matthias Frech, Johannes Gleitz, Nina Heiss, Bjoern Hock, Kai Schiemann, Frank Zenke